

Preliminary Clinical Data Show Potential For Addressable Market Expansion

Highlights

- **The global population of people with angle closure glaucoma is approximately 30 million¹ compared with 80 million people with open angle glaucoma¹.**
- **Preliminary clinical data show potential efficacy of iTrack™ products in treating angle closure glaucoma.**
- **Angle closure glaucoma is the dominant form of glaucoma in Asian countries and is not indicated for treatment by MIGS devices.**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary canaloplasty devices – *iTrack™* and *iTrack™ Advance* – were featured as part of the scientific program of the annual conference of Royal Australian and New Zealand College of Ophthalmologists (RANZCO) held in Perth, Australia, 20-23 October 2023.

Australian eye surgeon Nathan Kerr BHB, MBChB, MD, FRANZCO of Eye Surgery Associates, who is also Consultant Ophthalmologist at the Royal Victorian Eye and Ear Hospital and Principal Investigator (Glaucoma) at the Centre for Eye Research Australia (CERA), presented on the topic: *"Multicenter iTrack Canaloplasty Data Registry – Outcomes of Ab-Interno Canaloplasty Across Different Glaucoma Types and Severity"*.

The presentation addressed the 12-month clinical outcomes of 82 of the 367 glaucoma patients with 12 month follow up who underwent treatment with the *iTrack™* or *iTrack™ Advance* device. These patients form part of the *iTrack™* Global Data Registry.

Nova Eye Chief Commercial Officer, Kate Hunt, commented:

"While this data has not yet undergone peer review and noting that more patients will need to reach a minimum 12-month follow-up to draw any statistically meaningful conclusions from the data, we are particularly excited by this preliminary data for two reasons.

*First, it shows the effectiveness of our devices across all stages of open angle glaucoma severity. Unlike stent based MIGS, which are indicated in either mild, moderate or severe disease only, our *iTrack™* and *iTrack™ Advance* canaloplasty devices are indicated across all stages of open angle glaucoma.*

*Second, the data suggests that our *iTrack™* and *iTrack™ Advance* devices may play an*

important role in the treatment of angle closure glaucoma. Angle closure glaucoma is not currently indicated for treatment by MIGS devices and yet accounts for most glaucoma cases throughout Asia. This data highlights the potential to significantly increase the available market for iTrack™ and iTrack™ Advance.”

1. Market Scope “2023 Glaucoma Surgical Device Market Report”

Authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited.

– ENDS –

Company

Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Company

Kate Hunt
Chief Commercial Officer
+61 404 080 679
khunt@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT THE iTRACK GLOBAL DATA REGISTRY

Established in May 2022, the iTrack™ Global Data Registry is collecting prospective, multicentre, longitudinal data for canaloplasty in the treatment of glaucoma and currently counts approximately 400 canaloplasty procedures independently documented by surgeons from the United States, Canada, Europe and Australia. At least 500 canaloplasty procedures are expected to be entered into the Registry, providing a real-world assessment of the clinical utility of the Company’s iTrack™ and iTrack™ Advance canaloplasty devices.

ABOUT ANGLE CLOSURE GLAUCOMA AND OPEN ANGLE GLAUCOMA

Angle closure glaucoma is characterised by a narrowed or obstructed drainage angle in the and is associated with damage to the optic nerve. Angle closure glaucoma is the most common form of glaucoma in the Asian population. In its report “2023 Glaucoma Surgical Device Market Report”, Marketscope estimates that the current global population of people with angle closure glaucoma is 29.6 million. This compares with 80.5 million people with primary open angle glaucoma, the current target population for the Company’s iTrack™ and iTrack™ Advance canaloplasty devices.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally

invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com